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Abstract
Background: In studies on the genetics of human aging, we observed an age-related variation of the 3'APOB-
VNTR genotypic pool (alleles: Short, S, <35 repeats; Medium, M, 35–39 repeats; Long, L, >39 repeats) with the
homozygous SS genotype showing a convex frequency trajectory in a healthy aging population. This genotype was
rare in centenarians, thus indicating that the S alleles are unfavorable to longevity, while common in adults, thus
indicating a protective role at middle age. This apparent paradox could be due to possible effects exerted by the
above polymorphism on lipidemic parameters. Aim of the work was to get insights into these puzzling findings
Methods: We followed a double strategy. Firstly, we analyzed the average effects of S (αS), M (αM), and L (αL)
alleles on lipidemic parameters in a sample of healthy people (409 subjects aged 20–102 years) recruited in
Calabria (southern Italy). The (αS), (αM), and (αL) values were estimated by relating 3'APOB-VNTR genotypes to
lipidemic parameters, after adjustment for age, sex and body mass index (multiple regression). Then, we analyzed
the S alleles as susceptibility factors of Cardiovascular Atherosclerotic Disease (CD) in CD patients characterized
either by low serum HDL-Cholesterol or by high serum LDL-Cholesterol (CD-H and CD-L patients, 40 and 40
subjects respectively). The Odds Ratios (OR) were computed for carriers of S alleles in CD-H and CD-L patients
matched for origin, sex and age with controls extracted from the sample of healthy subjects.
Results: By the analysis of the healthy sample group we found that the S alleles lower the average values of serum
Total Cholesterol (αS = -5.98 mg/dL with [-11.62 ÷ -0.74] 95% confidence interval) and LDL-Cholesterol (αS = -
4.41 mg/dL with [-8.93 ÷ -0.20] 95% confidence interval) while the alleles M and L have no significant effect on the
lipidemic phenotype. In line with these findings, the analysis of CD patients showed that the S alleles are protective
as for CD-L (O.R. = 0.55 with [0.21 ÷ 0.98] 95% confidence interval) while neutral as for CD-H (O.R. = 0.75 with
[0.32 ÷ 1.60] 95% confidence interval).
Conclusion: On the whole, the S alleles would be advantageous in adults (by protecting from CD-L) while
dangerous in the elderly, probably by lowering serum cholesterol below a critical threshold. This could explain
the convex frequency trajectory of SS genotypes previously observed in a healthy aging population.
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Background
It is well known that the serum level of Low Density Lipo-
protein – Cholesterol (LDL-C) is positively correlated
with proneness to atherosclerosis and cardiovascular dis-
eases. Apolipoprotein B (ApoB) is the main component of
LDL and the variability of the APOB gene may play a role
in the genetic susceptibility to such diseases by modulat-
ing the average effects exerted by APOB variants on the lip-
idemic phenotype [1,2]. A VNTR polymorphism, which is
located 75 bp downstream the second polyadenylation
signal at the 3' end of the APOB gene (2p24-p23) has been
suggested as one of the factors which modulate liability to
coronary heart disease, at least in populations of Cauca-
sian ancestry [3,4] possibly through allele-specific expres-
sions of the APOB gene [5].
Recently, in gene/longevity association studies, we ana-
lyzed the changes of the gene pool relevant to the 3'APOB-
VNTR polymorphism in healthy aging populations. By re-
coding the 3'APOB-VNTR alleles into three size classes
(Small, S, <35 repeats; Medium, M, 35–39 repeats; Large,
L,  > 39 repeats) we found that the frequency of the
homozygous SS genotype was very low in oldest old sub-
jects [6] and decreased in the population following an
age-related convex trajectory [7]. The non linear trajectory
suggested that the SS genotype was protective in younger
individuals, while frail in the new scenario that comes out
when age increases [8]. This puzzling finding could be
due, at least in part, to a possible association between the
3'APOB-VNTR polymorphism and lipidemic parameters.
Aim of the present study was to check this idea by analyz-
ing the average effects of S (αS), M (αM), and L (αL) alleles
on lipidemic parameters in a sample group of healthy
subjects. Then, to check the indications given by the study
of the allele average effect, we also analyzed patients
affected by Cardiovascular Atherosclerotic Disease (CD)
who were characterized either by low serum HDL-Choles-
terol or by high serum LDL-Cholesterol (CD-H and CD-L
patients respectively).
Methods
Healthy group
The sampling was carried out in a well defined geographic
area (Calabria, southern Italy) taking care to minimize
possible heterogeneity factors as previously described [9].
The samples were recruited by an appropriate campaign
focused on University' students and staff (18- to 60-year
age range), thermal baths and University for the Elderly
(61- to 95-year age range); while the centenarians were
identified by consulting the Population Registers of the
Municipalities of Calabria, contacted by phone and then
visited. Routine blood analyses were carried out in each
subject and, in addition, subjects older than 60 years
underwent a complete clinical and geriatric assessment.
Subjects having blood parameters in the sex- and age-spe-
cific normal range, none taking regular medication, and
free of clinically overt pathologies were enrolled in the
study (169 males and 240 females; 20–102 years age-
range). In particular, centenarians were from the catego-
ries A and B previously described [10].
Patients
Eighty male patients affected by Cardiovascular Athero-
sclerotic Disease (46–80 years age-range) and character-
ized either by a low level of serum HDL-C (CD-H patients,
n = 40) or by a high level of serum LDL-C (CD-L patients,
n = 40) were recruited at the Italian National Research
Center on Aging (INRCA) in Cosenza (Calabria, southern
Italy). About 70% of the patients were settled in the hos-
pital, while the remaining were ambulatory visited. All the
patients were matched for ethnicity, origin, residence, age
and sex with the appropriate sub-group of healthy sub-
jects. Diagnostic criteria for the inclusion in the study are
reported in Table 1, while Table 2 shows lipidemic param-
eters in CD-H and CD-L patients.
All the subjects, both in the sample of healthy people and
in that of patients, were unrelated and had given their
written informed consent to the present study.
Molecular analyses
The 3'APOB-VNTR polymorphism was typed as described
[6] on PCR-amplified DNA extracted from blood buffy
coats.
As for the lipidemic parameters, serum Total Cholesterol
(TC), HDL-Cholesterol (HDL-C), Tryglycerides (TG) were
measured in each subject (12 hrs. overnight fast) by enzy-
matic colorimetric method with commercial kits (Dade
Behring) in an automated chemistry analyzer (Dimen-
sionR Clinical Chemistry System). LDL-Cholesterol (LDL-
C) was estimated by the Friedewald's formula [11].
Statistical analyses
The αS, αM, αL average effects exerted by S, M, and L alleles
respectively on the lipidemic parameters were estimated
in the sample of healthy subjects according to Chris-
tiansen and Feldman [12] after verification of the Hardy-
Weinberg equilibrium (χ2 test). Lipidemic data were used
after removing trends due to age, sex and Body Mass Index
(computed according to the formula: BMI = weight [Kg]/
height [m2]) by multiple regression. The 95% confidence
intervals of αS, αM, αL were calculated by bootstrap (1,000
replications, MATLAB Statistic toolbox).
The Odds Ratios (OR) in CD-H and CD-L were estimated
for the carriers of S  alleles (homozygous plus hetero-
zygous subjects) with respect to sex- and age-matched
controls extracted from the sample of healthy subjects.BMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/3
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The 95% confidence intervals of OR were computed by
bootstrap (1,000 replications, MATLAB Statistic toolbox).
Results
Estimation of allele-average effects
The genotype/phenotype relationship between 3'APOB-
VNTR variability and lipidemic parameters was analyzed
in the sample of healthy subjects by estimation of allelic
average effects on lipidemic parameters. Tables 3 and 4
summarize lipidemic data (stratified according to age and
sex) and genetic data respectively. The allele average
effects αS, αM, αL on serum TC, HDL-C, LDL-C and TG,
after adjustment for age, sex and Body Mass Index, are
shown in Table 5, where it can be seen that the S alleles
significantly lower the serum level of both TC and LDL-C
(95% c.i. non including 0).
3'APOB-VNTR alleles in CD
The genotypic and allelic frequencies in CD-H and CD-L
patients, with those in sex- and age-matched controls used
to compute OR values, are shown in the Table 6.
According with the results of the study of allele average
effects, that showed a specific effect exerted by the S alleles
on both TC and LDL-C, we found that the S alleles are pro-
tective in CD-L (OR = 0.55; [0.21 ÷ 0.98] 95% c.i.) while
neutral in CD-H (O.R. = 0.75; [0.32 ÷ 1.60] 95% c.i.).
Discussion
The study showed an allele-specific association between
the 3'APOB-VNTR variability and lipidemic parameters in
a southern Italian population. Although association stud-
ies should be carefully considered due to the possibility of
false positive findings, we are confident that the results of
the present study are reliable for three reasons. Firstly, the
Table 1: Diagnostic criteria used to identify CD-H and CD-L patients with Cardiovascular Atherosclerotic Disease (CD)
Patients with Cardiovascular Atherosclerotic Disease (CD)
Coronary Artery Disease
- Myocardial Infarction assessment of myocardial ischaemia (exercise test and/or 
myocardial perfusion scintigraphy)
- Angina Pectoris
- PTCA (Percutaneous Transfemoral 
Coronary Angioplasty)
- CABG (Coronary Artery By-pass Graft)
and/or
Carotid Atherosclerosis assessment of stenosis ≤50%, occlusion (echo-color-doppler)
and/or
Peripheral Arterial Disease echo-color-doppler; Index's Windsor <0.8
and with dyslipidemia
HDL-Cholesterol ≤35 mg/dl (CD-H patients)*
LDL-Cholesterol ≥170 mg/dl (CD-L patients)*
With or Without
Tryglycerides ≥170 mg/dl
*Cutoff values were chosen on the basis of the average serum levels of HDL-C and LDL-C in southern Italian adult males not affected by any 
clinically manifest disease.
Table 2: Lipidemic parameters (mg/dL) in the samples of CD patients (46–80 years age range). Mean values with standard deviation in 
parenthesis.
CD-H Patients (n= 40; median age 64 years) CD-L Patients (n= 40; median age 62 years)
TC 185.7 (44.7) 284.6 (34.1)
HDL-C 27.8 (3.2) 45.4 (9.9)
LDL-C 125.6 (32.1) 207.3 (30.6)
TG (Log10) 2.15 (0.2) 2.2 (0.2)
CD-H: Cardiovascular Disease with low level of HDL-C; CD-L: Cardiovascular Disease with high level of LDL-C; TC: serum Total Cholesterol; 
HDL-C: serum HDL-Cholesterol; LDL-C: serum LDL-Cholesterol (TC – HDL-C – TG/5); TG: serum TryglyceridesBMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/3
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lowering effect exerted by the 3`APOB-VNTR short alleles
on serum TC and LDL-C had been previously observed in
a sample of healthy people from Belgrade [13]. Secondly,
the typing of a moderate number of neutral markers
spread across the genome [14] did not show stratification
in the sample we analyzed (unpublished results). Thirdly,
and mostly important, the significant lowering effect
exerted by the S alleles on serum LDL-C (Table 5) is in line
with the finding that these alleles are protective for CD-L
(O.R. = 0.55 with [0.21 ÷ 0.98] 95% confidence interval)
while neutral for CD-H.
The average effect exerted by the S alleles on TC and LDL-
C, and their protective role in CD-L, could explain why the
SS  homozygous genotype was over-represented in an
adult age-class of people selected for healthy status [7].
However, as age increases, both TC and LDL-C serum lev-
els decline as shown by the population data in Table 3. In
this new physiological situation, the SS genotypes, that
was protective at adult age, may turn out to be detrimental
at old age, because the serum levels of TC and LDL-C may
drop out below a critical threshold. In fact, in very old
people, a high serum TC concentration is associated with
increased survival [15,16].
Conclusions
The data here presented showed that the S alleles of the
3'APOB-VNTR polymorphism (less than 35 repeats) are
Table 3: Lipidemic parameters (mg/dL) in the sample of healthy subjects stratified for age. Mean values with standard deviation in 
parenthesis.
Males
Age 20–45 yrs. n = 54 46–80 yrs. n = 105 ≥100 yrs. n = 10
TC 206.8 (45.8) 216.8 (43.4) 185.3 (32.7)
HDL-C 48.9 (9.9) 57.1 (16.5) 47.0 (14.0)
LDL-C 132.9 (37.9) 137.4 (37.3) 114.7 (27.6)
TG (Log10) 2.0 (0.2) 2.1 (0.2) 2.0 (0.1)
Females
Age 20–45 yrs. n = 120 46–80 yrs. n = 80 ≥100 yrs n = 40
TC 191.7 (32.7) 224.8 (48.6) 179.1 (25.2)
HDL-C 63.7 (13.2) 65.3 (15.4) 50.2 (13.7)
LDL-C 113.1 (27.7) 142.7 (41.8) 103.9 (24.1)
TG (Log10) 1.8 (0.2) 2.0 (0.2) 2.0 (0.2)
TC: serum Total Cholesterol; HDL-C: serum HDL-Cholesterol; LDL-C: serum LDL-Cholesterol (TC – HDL.C – TG/5); TG: serum Tryglycerides
Table 4: 3'APOB-VNTR genotypes, with Hardy-Weinberg equilibrium (HWE) expected values, in the sample of healthy subjects. 
Absolute and relative allelic frequencies (with standard errors) are also shown.
Genotypes (n = 409) Counts *HWE
SS 15 17.05
SM 119 108.81
SL 18 24.09
MM 166 173.65
ML 82 76.89
LL 98 . 5 1
Alleles (n = 818) Absolute Relative ± SE
S 167 0.204 ± 0.014
M 533 0.652 ± 0.017
L 118 0.144 ± 0.012
*χ2 = 3.44 with 3 d.f.; p = 0.328 Alleles: S < 35 repeats; M 35–39 repeats; L > 39 repeats.BMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/3
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associated with low levels of both TC and LDL-C in a pop-
ulation from southern Italy. This finding can explain why
these alleles were over-represented in a sample of healthy
adults [7] while rare in a sample of CD-L patients, charac-
terized by high level of serum LDL-C. From this point of
view, the S  alleles could be regarded as beneficial for
healthy ageing. However, the observation that these alle-
les are rare in centenarians [6,7] indicates that they are
detrimental for longevity, probably because of their effect
on lipidemic parameters in the physiological background
of very old persons. On the whole, the study confirms that
genetic risk factors are age-specific and gets possible
insights on another "paradox of centenarians" [17].
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